...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer
【24h】

Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer

机译：雄激素剥夺治疗前血清睾丸激素和体重指数对转移性前列腺癌的预后影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: Although the impact of testosterone or obesity on the efficacy of androgen-deprivation therapy (ADT) has been reported, there exist few comprehensive analyses on the impact of these factors on ADT outcome. Therefore, in the present study, we investigated the relationship between serum testosterone or body mass index (BMI) and prognosis among men treated with primary ADT for metastatic prostate cancer. Patients and Methods: The study included fifty-six Japanese patients with prostate cancer treated at our Institution from 2000 through 2012. The relationship between serum testosterone or BMI and progression-free survival, cancer-specific survival, and overall survival among men with metastatic prostate cancer treated with primary ADT was examined. Results: The median of serum testosterone and BMI were 397 ng/dl (interquartile range (IQR), 278-464 ng/dl) and 21.9 kg/m(2) (IQR, 19.2-23.6 kg/m(2)), respectively. Median progression-free survival, cancer-specific survival, and overall survival were 23.2 months, 68.9 months, and 68.1 months, respectively. Among clinicopathological parameters, the lowest-quartile group of serum testosterone level was a significant predictor of poor cancer-specific survival and overall survival as well as survival from castration resistance. However, BMI was not associated with prognosis. Conclusion: Serum testosterone level, but not obesity, is a prognostic factor for outcome including survival after getting castration-resistant prostate cancer in men with metastatic prostate cancer having undergone primary ADT.
机译：目的：尽管已经报道了睾丸激素或肥胖症对雄激素剥夺疗法（ADT）疗效的影响，但很少有关于这些因素对ADT结局的影响的综合分析。因此，在本研究中，我们调查了接受转移性前列腺癌原发性ADT治疗的男性中血清睾丸激素或体重指数（BMI）与预后之间的关系。患者与方法：该研究包括2000年至2012年在我们机构接受治疗的56例日本前列腺癌患者。血清睾丸激素或BMI与无进展生存期，癌症特异性生存期以及转移性前列腺癌男性总生存期之间的关系检查了用原发性ADT治疗的癌症。结果：血清睾丸激素和BMI的中位数分别为397 ng / dl（四分位间距（IQR），278-464 ng / dl）和21.9 kg / m（2）（IQR，19.2-23.6 kg / m（2）），分别。中位无进展生存期，癌症特异性生存期和总生存期分别为23.2个月，68.9个月和68.1个月。在临床病理参数中，血清睾丸激素水平最低的四分位数组是癌症特异性生存率和总体生存率以及去势抵抗生存率低的重要预测指标。但是，BMI与预后无关。结论：血清睾丸激素水平（而非肥胖）是包括原发性ADT的转移性前列腺癌男性在去势抵抗性前列腺癌后生存的预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号